Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec:24:100875.
doi: 10.1016/j.conctc.2021.100875. Epub 2021 Nov 16.

Meeting the challenges of retention and enrollment of study participants in clinical trials during the COVID-19 pandemic from the study leadership perspective: Experience from the Zoster Eye Disease Study (ZEDS)

MeeLee Tom  1 , Elisabeth J Cohen  2 , Carlos LopezJimenez  1 , Judith S Hochman  3 , Andrea B Troxel  4 , Bennie H Jeng  5
Affiliations

Meeting the challenges of retention and enrollment of study participants in clinical trials during the COVID-19 pandemic from the study leadership perspective: Experience from the Zoster Eye Disease Study (ZEDS)

MeeLee Tom et al. Contemp Clin Trials Commun. 2021 Dec.

Abstract

Purpose: To describe steps taken that enabled a high rate of retention and early resumption of enrollment in the Zoster Eye Disease Study (ZEDS), a randomized controlled trial funded by the National Eye Institute, during the first 13 months (3/1/2020-3/31/2021) of the COVID-19 pandemic.

Methods: A number of responses were implemented in ZEDS when the focus shifted to retention of study participants at the beginning of the pandemic including frequent communication with the participating clinical centers (PCCs) about remote visits, local lab work, shipping study medication, and completion of revised case report forms. Additional payments were provided to the PCCs. Remote activation of PCCs continued. Screening and enrollment visits gradually resumed when allowed.

Results: Communication with PCCs increased, and average attendance at monthly coordinator teleconferences went up from 17 to 47. Remote visits peaked in April 2020, accounting for 75% (33/44) of study visits, then declined to less than 10% of study visits beginning August 2020. Overall, 97% (590/609) of study visits were completed. Only 5.5% (9/165) of study participants withdrew consent, and 2.4% (4/165) were lost to follow-up. Enrollment returned to pre-pandemic levels by September 2020.

Discussion: Strong communication and unwavering commitment, combined with the technological capability for remote work, visits, and shipment of study medication, were key to the successful retention of study participants and resumption of enrollment.

Conclusions: Rapid responses to challenges to trials caused by the COVID-19 pandemic can enable them to continue successfully and provide insights into the planning of future trials.

Keywords: COVID-19 pandemic; Clinical trial; Enrollment; Herpes zoster ophthalmicus; Retention; Zoster Eye Disease Study.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

Cited by

References

    1. Cohen E., Hochman J., Troxel A., Colby K., Jeng B.H. The zoster eye disease study (ZEDS): rationale and design. Cornea. 2021 In press. - PubMed
    1. Tan A.C., Ashley D.M., Khasraw M. Adapting to a pandemic - conducting oncology trials during the SARS-CoV-2 pandemic. Clin. Cancer Res. : J. Am. Assoc. Cancer Res. 2020;26(13):3100–3103. - PMC - PubMed
    1. Waterhouse D.M., Harvey R.D., Hurley P., Levit L.A., Kim E.S., Klepin H.D., et al. Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American society of clinical oncology survey. JCO Oncol. Pract. 2020;16(7):417–421. - PubMed
    1. Mitchell E.J., Ahmed K., Breeman S., Cotton S., Constable L., Ferry G., et al. It is unprecedented: trial management during the COVID-19 pandemic and beyond. Trials. 2020;21(1):784. - PMC - PubMed
    1. Shiely F., Foley J., Stone A., Cobbe E., Browne S., Murphy E., et al. Managing clinical trials during COVID-19: experience from a clinical research facility. Trials. 2021;22(1):62. - PMC - PubMed